Advancing novel antidepressants and anxiolytics based on clinically validated mechanisms powered by our Glyph™ platform.
Uniquely designed to enable oral bioavailability, avoid first-pass metabolism and reduce hepatotoxicity and other side effects.
Press Release - 2024-04-09
Seaport
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
Papers
Nature Metabolism
Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity
Papers
Frontiers in Pharmacology
Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport
